Steady-state equilibrium phase inversion recovery ON-resonant water suppression (IRON) MR angiography in conjunction with superparamagnetic nanoparticles. A robust technique for imaging within a wide range of contrast agent dosages. by Gitsioudis, G. et al.
  
Serveur Académique Lausannois SERVAL serval.unil.ch 
Author Manuscript 
Faculty of Biology and Medicine Publication 
This paper has been peer-reviewed but dos not include the final publisher 
proof-corrections or journal pagination. 
Published in final edited form as:  
 
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains 
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article. 
 
Title: Steady-state equilibrium phase inversion recovery ON-resonant 
water suppression (IRON) MR angiography in conjunction with 
superparamagnetic nanoparticles. A robust technique for imaging 
within a wide range of contrast agent dosages. 
Authors: Gitsioudis G, Stuber M, Arend I, Thomas M, Yu J, Hilbel T, 
Giannitsis E, Katus HA, Korosoglou G 
Journal: Journal of magnetic resonance imaging : JMRI 
Year: 2013 Oct 
Volume: 38 
Issue: 4 
Pages: 836-44 
DOI: 10.1002/jmri.24043 
 
Steady-State Equilibrium Phase Inversion Recovery ON-
resonant Water Suppression (IRON) Magnetic Resonance
Angiography in Conjunction with Superparamagnetic
Nanoparticles. A Robust Technique for Imaging within a Wide
Range of Contrast Agent Dosages
Gitsios Gitsioudis, MD1, Matthias Stuber, PhD2,3, Ingolf Arend1, Moritz Thomas4, Jing Yu,
PhD2, Thomas Hilbel, MD1,4, Evangelos Giannitsis, MD1, Hugo A. Katus, MD1, and
Grigorios Korosoglou, MD1
1University of Heidelberg, Department of Cardiology, Heidelberg, Germany 2Russell H. Morgan
Department of Radiology and Radiological Sciences, Division of MR Research, Johns Hopkins
University School of Medicine, Baltimore, Maryland, USA 3Center for Biomedical Imaging (CIBM),
University Hospital Lausanne, Switzerland 4University of Applied Sciences Gelsenkirchen,
Department of Physical Engineering, Gelsenkirchen, Germany
Abstract
Objectives—To investigate the ability of inversion recovery ON-resonant water suppression
(IRON) in conjunction with P904 (superparamagnetic nanoparticles which consisting of a
maghemite core coated with a low-molecular-weight amino-alcohol derivative of glucose) to
perform steady-state equilibrium phase magnetic resonance angiography (MRA) over a wide dose
range.
Materials and Methods—Experiments were approved by the institutional animal care
committee. Rabbits (n=12) were imaged at baseline and serially after the administration of 10
incremental dosages of 0.57–5.7 mgFe/Kg P904. Conventional T1-weighted and IRON MRA were
obtained on a clinical 1.5-T scanner to image the thoracic and abdominal aorta, and peripheral
vessels. Contrast-to-noise ratios (CNR) and vessel sharpness were quantified.
Results—Using IRON MRA, CNR and vessel sharpness progressively increased with
incremental dosages of the contrast agent P904, exhibiting constantly higher contrast values than
T1-weighted MRA over a very wide range of contrast agent doses (CNR of 18.8±5.6 for IRON
versus 11.1±2.8 for T1-weighted MRA at 1.71 mgFe/kg, p=0.02 and 19.8±5.9 for IRON versus
−0.8±1.4 for T1-weighted MRA at 3.99 mgFe/kg, p=0.0002). Similar results were obtained for
vessel sharpness in peripheral vessels, (Vessel sharpness of 46.76±6.48% for IRON versus
33.20±3.53% for T1-weighted MRA at 1.71 mgFe/Kg, p=0.002, and of 48.66±5.50% for IRON
versus 19.00±7.41% for T1-weighted MRA at 3.99 mgFe/Kg, p=0.003).
Conclusion—Our study suggests that quantitative CNR and vessel sharpness after the injection
of P904 are consistently higher for IRON MRA when compared to conventional T1-weighted
MRA. These findings apply for a wide range of contrast agent dosages.
Address for correspondence: Grigorios Korosoglou, MD, University Hospital of Heidelberg, Department of Cardiology, Im
Neuenheimer Feld 410, 69120 Heidelberg, Germany, grigorios.korosoglou@med.uni-heidelberg.de, Tel: +49 (0)6221 56 37764, Fax:
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Introduction
Contrast-enhanced magnetic resonance angiography (MRA) is an imaging technique which
aids the diagnosis of peripheral, carotid and coronary artery disease in a multitude of clinical
settings1–3. The short intravascular half-life time of clinically used low-molecular weight
gadolinium chelates, however, limits the imaging time window and therefore the spatial
resolution of the resultant images4–6. Furthermore, the use of gadolinium based contrast
agents was recently linked to nephrogenic systemic fibrosis, limiting their applicability in
certain patient groups7,8.
Depending on particle size, surface structure and other factors, superparamagnetic
nanoparticles on the other hand, remain in the vascular space for prolonged periods of time,
permitting the acquisition of high spatial resolution MRA9–11. In this regard, we and others
have recently demonstrated the ability of off-resonance imaging techniques including ‘Off-
Resonance Contrast Angiography’ (ORCA) and ‘Inversion Recovery with ON-Resonant
water suppression’ (IRON) to provide signal-enhanced visualization of blood vessels and
simultaneously suppress background signal, obviating the need for image subtraction12–14.
Due to (1) the long half-life time of superparamagnetic nanoparticles in the blood-pool, and
(2) the very high signal obtained both from T1-shortening and from off-resonant protons,
IRON MRA was shown to be well-suited for 3D imaging, which inherently allows
prolonged scanning times13,14. However, in previous studies, the doses of ultrasmall
superparamagnetic nanoparticles injected in animals were much higher than the
recommended clinical dose of up to 4 mgFe/Kg in humans which is equivalent to 9.5% of
total body iron for females and 8% for males, equaling the iron load of 1–2 blood units15,16.
Therefore, our purpose was to investigate the feasibility of IRON in conjunction with
superparamagnetic nanoparticles for contrast-enhanced MRA within a range of dosages
applicable for humans. Experiments were performed in rabbits, aiming at the visualization
of the thoracico-abdominal aorta as well as of small peripheral arteries, and the resultant
IRON MRA images were compared to conventional T1-weighted acquisitions.
Materials and Methods
Animals and Contrast Agents
The studies were approved by our local institutional animal care and use committee
(Karlsruhe, Baden-Württemberg, Germany). Experiments were conducted in 12 rabbits
(3.2–4.0 kg), which intramuscularly received ketamine (50 mg/kg) and xylazine (20 mg/dl)
for general anaesthesia during the imaging studies. Superparamagnetic nanoparticles
contrast material (P904) was provided by Guerbet (Villepinte, France). P904 consists of a
maghemite core, which is coated with a low-molecular-weight amino-alcohol derivative of
glucose17. Its coating represents approximately 2000 hydroxyl groups per nanoparticles
(particle size of 21 nm). P904 shows higher relaxivities r1 and r2 (14 and 87 mM−1sec−1) as
the reference-standard contrast agent ferumoxtran-10, measured in water at 1.42 T and
37°C17. The highest dose of USPIO contrast material applicable for imaging in humans is 4
mg Fe/kg of body weight15,18,19. The plasma half-life for P904 has shown to be 3.5 h in
rabbits, which is markedly lower than that of ferumoxtran-10 which is 24–72 h17. The
lowest dose of superparamagnetic nanoparticles, visible by MRI was reported to be in the
order of 1013–14 iron oxide particles / gram tissue for Monocrystalline Iron Oxide
Nanocompounds (MION), which would correspond to an intravenous iron administration of
~0.4–0.6mgFe/Kg20. Based on these data, in our study a total dose of 5.7 mg Fe/Kg was
administrated in ten incremental steps, i.e. each of 0.57 mgFe/Kg. Imaging was performed at
baseline and after the administration of each incremental dosage of the contrast agent (flow
diagram illustrated in Figure 1). Venous blood was obtained from all rabbits before and after
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contrast material application for biochemical analysis of kidney (creatinine) and hepatic
function (transaminase) and cardiac necrosis parameters (creatine kinase, high-sensitive
Troponin T, Table 1).
Magnetic Resonance Angiography (MRA)
MR imaging was performed on a 1.5-T clinical scanner (Intera Achieva; Philips Healthcare,
Best, The Netherlands) using a 32-element cardiac phased-array receiver coil. Images were
obtained at baseline and serially after the administration of incremental dosages of 0.57
mgFe/Kg P904 (Figure 1). For all imaging procedures, volume shimming was used. Scans
were performed without parallel imaging, because such techniques would not allow for
accurate assessment of SNR and CNR in the resultant images.
(1) Conventional T1-weighted MRA—For T1-weighted MRA three-dimensional
gradient-echo (fast-field-echo, FFE) images were obtained using the following parameters13:
Time Repetition/Time Echo (TR/TE)=25/4.5 ms, flip angle (FA)=20°, field-of-view
(FOV)=200×150, acquired voxel size 0.5×0.5×1.0 mm3 and 400×300 image matrix. 70
coronal slices were acquired within a total scan duration of 4 min, resulting in a total volume
thickness of 7 cm.
(2) IRON MRA—For IRON MRA, an on-resonant frequency-selective IRON suppression
prepulse with BWIRON of 100 Hz, a duration of τ=50 msec and an excitation angle αIRON of
100° was used, as described previously13. Conventional fat saturation was achieved by
applying a prepulse preceding the IRON prepulse with a −220 Hz frequency offset, a 100 Hz
bandwidth, and a 105° FA. Imaging parameters were: TR/TE=5.3/2.0 ms, FA=20°,
FOV=120×130 mm, acquired voxel size=0.5×0.5×2.0 mm3 and 248×254 image matrix. 30
coronal slices were acquired within a total scan duration of 5 min, resulting in a total volume
thickness of 6 cm.
MRA Image Analysis
Image analysis was performed with the Soapbubble software tool (Release 5.1 for PRIDE
V4.*+V5, Philips Healthcare, Best The Netherlands), as described previously21. Signal-to-
noise (SNR) and contrast-to-noise ratios (CNR) were calculated in vivo by placing regions
of interest (ROIs) in the background, in the aortic lumen and in adjacent muscle tissue using
original, reformatted magnitude images. For MRA of the thoracic aorta three ROIs were
drawn in the ascending aorta, aortic arch and descending aorta, respectively (Figure 2). For
MRA of the abdominal aorta and peripheral vessels, also three ROIs were drawn in the
suprarenal, and infrarenal aorta, and at the iliacal bifurcation (Figure 2). Vessel sharpness
was quantified in the common iliac arteries ~20 mm distal from the aortic bifurcation.
Care was taken to standardize ROI size and placement for better comparison between image
sets. The size of the ROI in arbitrary units was 71.45±14.72 for ROI placed in vessels,
75.71±18.43 for ROI placed in the adjacent muscle and 7343.61±1548.22 for ROI placed in
the background.
SNR and CNR were calculated using the following equations21: SNR = (IBlood)/SDEVAir
and CNR =(IBlood − IMuscle)/SDEVAir. Vessel sharpness was calculated using the
equation22: , where i represents the index of each point at
the vessel wall, Edge the step size of the function at the step position, N the number of edge
points, and p the user defined drawing point along the vessel. Besides SNR and CNR
analysis, vessel sharpness enables the quantification of vessel conspicuity and is based on a
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derivative of the image. On such derivative images, the local signal intensity at the vessel
border is a measure of edge definition or signal intensity change relative to the vessel
surroundings.
Statistical Analysis
Data are presented as means ± one standard deviation. Differences in SNR, CNR and vessel
sharpness between T1 weighted and IRON-MRA for the same doses of contrast agent were
evaluated using 2-tailed unpaired t-tests. Calculations were performed using statistical
software (MedCalc® Software, Version 11.4.2.0, Mariakerke, Belgium). For estimation of
inter- and intra-observer variability 20 randomly selected cases were analyzed by two
independent observers in terms of SNR, CNR and vessel sharpness. Readings were
separated by 4 weeks to minimize recall bias. Differences were considered statistically
significant at p<0.05.
Results
Representative examples of the rabbit thoracic and abdominal aorta imaged during
incremental dosages of P904 using T1-weighted and IRON MRA can be appreciated in
Figures 3 and 4. Corresponding images of the aorta at the level of the aortic bifurcation are
shown in Figure 5.
For conventional T1-weighted MRA, CNR and vessel sharpness initially increased after
injection of P904 both in the thoracico-abdominal aorta and in peripheral vessels up to a
dosage of 1.14 mgFe/kg (SNR (CNR) of 14.9±4.57 (9.0±2.8) for IRON versus 20.9±4.75
(10.9±2.8) for T1-weighted MRA, p=0.23 and vessel sharpness of 44.9±6.0% for IRON
versus 32.7±6.3% for T1-weighted MRA, p=0.003, at 0.57 mgFe/Kg). Subsequently, SNR,
CNR and vessel sharpness decreased with further increasing dosages (Figure 6A–C).
In contrast, using IRON MRA, SNR, CNR and vessel sharpness progressively increased
with incremental dosages of the contrast agent P904, exhibiting constantly higher contrast
values than T1-weighted MRA over a very wide range of the clinically applicable dosages
(CNR of 18.8±5.6 for IRON versus 11.1±2.8 for T1-weighted MRA at 1.71 mgFe/kg,
p=0.02 and 19.8±5.9 for IRON versus −0.8±1.4 for T1-weighted MRA at 3.99 mgFe/kg,
p=0.0002), (Figure 6B). Similar results were observed for vessel sharpness in peripheral
vessels, where IRON-MRA also exhibited constantly higher values than T1-weighted MRA
within the clinically applicable dosage range (vessel sharpness of 46.76±6.48% for IRON
versus 33.20±3.53% for T1-weighted MRA at 1.71mgFe/Kg, p=0.002, and of 48.66±5.50%
for IRON versus 19.00±7.41% for T1-weighted MRA at 3.99 mgFe/Kg, p=0.003), (Figure
6C).
Observer Variabilities
Quantification of SNR, CNR and vessel sharpness were reproducible exhibiting low intra-
and interobserver variabilities of 8.1%, and 4.2% for SNR, 8.9% and 5.2% for CNR and
4.6% and 4.2% for vessel sharpness, respectively.
Discussion
To our knowledge, this is the first study that demonstrates the feasibility of inversion
recovery ON-resonant water suppression (IRON) imaging in conjunction with
superparamagnetic nanoparticles (P904) for steady-state equilibrium phase MRA within a
wide range of dosages applied in human studies15,18. IRON MRA exhibited very high
contrast between the blood-pool and the surrounding tissue without the need for image
subtraction. The vessel conspicuity provided by IRON MRA surpassed that provided by
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conventional T1-weighted techniques in terms of SNR, CNR and resultant vessel sharpness.
These effects remained constant over a wide range of contrast agent dosages resulting in
very robust contrast behavior.
Several non-contrast and contrast enhanced angiography techniques have been previously
described, aiming at the visualization of peripheral or coronary vessels. Contrast enhanced
MRA on the other hand, depends on intravenous application of contrast material and is a
robust imaging technique with a multitude of clinical applications23. Gadolinium (Gd)-based
contrast agents are routinely used for contrast-enhanced MRA, increasing vascular
conspicuity by decreasing the T1-relaxation time of blood. However, the short arterial
imaging window before intravenous and extracellular distribution consecutively results in a
short arterial imaging window which governs the maximum spatial resolution and blood-
tissue contrast that can be obtained24,25.
In the present study we demonstrated for the first time the ability of the IRON technique in
conjunction with superparamagnetic nanoparticles, administrated within the range of the
dose applied in human clinical studies to visualize blood vessels with high spatial resolution
in an experimental rabbit model. The prolonged intravascular plasma half-life of P904
allowed for 3D T1-weighted acquisitions with high spatial resolution and CNR. However, in
agreement with theoretical considerations, competing  effects due to susceptibility effects
are unavoidable with increasing dosages of P904, even with ultra-short echo times26,27. This
resulted in increasing signal void within the vessels of interest causing decreased SNR, CNR
and vessel sharpness with increasing P904 doses in our study. IRON MRA on the other
hand, provided high intravascular SNR after P904 administration, which, in conjunction
with the simultaneous background suppression resulted in very high intravascular contrast.
Thus, intravascular contrast was ~60% higher for IRON compared to T1-weighted MRA
after the administration of clinically applicable contrast agent doses up to 4.0 mg Fe/Kg.
This is attributable to the dual origin of positive signal originating both from off-resonant
protons and from T1 recovery14. Furthermore, vessel sharpness was markedly higher in the
aorta with IRON than in conventional T1-weighted MRA in all applied concentrations of
P904. In the past the IRON sequence was used in combination with the long-circulating
monocrystalline iron oxide nanoparticle (MION)-47 for contrast material–enhanced
magnetic resonance (MR) angiography by Korosoglou et al.13. Using 1.27 mgFe/Kg or 3.96
mgFe/Kg of MION-47 and comparing with conventional T1-weighted MRA they showed
that IRON MRA provides high intravascular contrast over a long time and without the need
for image subtraction. It remains to be elucidated in future studies whether conventional T1-
weighted or IRON MRA is the adequate choice.
As previously described the minimum of signal intensity with IRON MRA depends on
tissue characteristics and the vessel orientation relative to the main magnetic field14. As a
result, edge enhancement effects occur in vessels perpendicular to the fold-over-direction as
shown in Figure 4, which may have led to an overestimation of the acquired vessel
sharpness. However, vessel conspicuity was similar between the aorta and the renal artery,
while computation of vessel sharpness in the latter would have been hindered by the close
proximity of the renal veins.
Potential (pre-) clinical applications
Because of the very high intravascular signal obtained by IRON MRA, this modality may
provide adequate signal in very small vessels as shown for peripheral iliac rabbit arteries in
our study, which may not be detectable using conventional MR-techniques. This may be
useful for the evaluation of small collateral vessels, in the progress of arteriogenesis or for
the monitoring of angiogenesis suppression therapies in cancer. The clinical application of
IRON off-resonance angiography may be limited by frequency shift and edge enhancement
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in vessels with extreme tortuosity. The dual origin of signal enhancement with IRON
however, originating from both off-resonant protons and T1-recovery, the latter being
orientation independent, may help to circumvent such limitations. Whether a broad
application of IRON off-resonance angiography in clinical realm may be limited by the
induced frequency shift and edge enhancement remains to be elucidate in future studies.
Furthermore, as coronary MRA remains a challenging task for clinical routine applications.
Due to the relation between scan time and SNR, the fact that IRON MRA provides higher
signal compared to conventional techniques (originating both from off-resonant protons and
from T1-recovery) may be exploited to further reduce scan time for MRA in such future
experiments. The fact that our observations were obtained using a clinical 1.5 T scanner, and
using P904, a contrast agent similar to ferumoxtran (particle size 30–35 nm, plasma half-life
24–30 hours) both indicate translational potential for human use. In this regard, ferumoxytol
is currently clinically approved for iron-replacement treatment in patients with chronic renal
failure28,29. Additional, improvement in signal intensity could be achieved using a 3.0 T
scanner20. Furthermore, in contrast to gadolinium-based contrast agents, nephrogenic
systemic fibrosis has not been described in superparamagnetic nanoparticles. However,
minor changes in PTT (partial thromboplastin time) have been described for iron-based
contrast agents without leading to clinically significant bleeding. Such changes were
attributed to a transient decrease in factor XI activity30. In general, USPIOs are well
tolerated without significant side effects in human trials31. Thus, in patients with renal
failure such nanoparticles may represent a valuable alternative for contrast-enhanced
MRA32.
Our study has some limitations. The number of animals studied was relatively small.
However, the magnitude of contrast enhancement was very similar among animals as
evidenced by the small standard deviation of all quantitative measurements. In addition,
contamination of the venous blood pool after the administration of superparamagnetic
nanoparticles cannot be avoided by IRON MRA. But this represents a general problem with
steady state MRA, where the discrimination of neighboring arteries and veins may be
impaired. Besides, as previously described by Vonken et al. edge enhancement effects in the
fold-over direction occur dependent on the vessel orientation relative to the main magnetic
field. This indeed poses a potential limitation for IRON MRA of small or tortuous vessels.
Next, long TE resulted during scan protocol optimization possibly due to gradient
limitations with our 1.5 Tesla scanner by choosing TE automatically as “shortest”, with
similar parameters as were published in previous studies and having activated the flow
compensation13. This may account for the suboptimal performance of T1-weighted MRA
due to signal loss with increasing T2* values. The spatial resolution of T1-weighted and
IRON MRA was not identical. However, all the imaging parameters including the total scan
time, the scan volume and the spatial resolution were optimized experimentally in order to
reach optimal image quality for each technique individually. During this developmental
phase we aimed at optimizing both vessel conspicuity and spatial resolution for adequate
visualization of both the thoracico-abdominal aorta and peripheral arteries. The lower
resolution in slice selection direction for in IRON MRA supports higher SNR and CNR
values. Last, in humans Hamm et al. recently showed that the SPIO SHU 555 A causes a
transient increase of aPTT31. However, the normal range of aPTT was not exceeded. Such
changes were not expected to translate to increased bleeding risk for the patients. However,
patients with increased bleeding risk would possibly have to be excluded from such clinical
studies in the future. Finally, the fact that the contrast agent we used is not approved for
clinical use is a limitation.
In conclusion, IRON MRA provides significantly higher blood-to-tissue contrast both in the
aorta and in small peripheral rabbit vessels compared to conventional T1-weigthed
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angiography within the dose range applicable for clinical human use. High CNR and vessel
sharpness remain stable over a wide range of contrast agent concentrations, which may
possibly allow for more robust MRA acquisitions in clinical applications. Especially, in light
of clinical MR setting used in our study and the duration of the IRON MRA acquisitions (~5
min) the translation of our findings to the clinical realm appears promising.
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Figure 1.
Schematic illustration of the P904 administration in animal studies.
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Figure 2.
ROI positioning in the thoracic (a & d) and the abdominal aorta (b–c & e–f) with T1 MRA
(upper row) and IRON MRA images (lower row) for SNR and CNR analysis. BG indicates
Background ROI; L1-3, Lumen ROIs and M, Muscle ROI.
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Figure 3.
Representative examples of the rabbit thoracic aorta imaged during incremental dosages of
P904 using T1-weighted and IRON MRA
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Figure 4.
Representative examples of the rabbit abdominal aorta imaged during incremental dosages
of P904 using T1-weighted and IRON MRA. Edge enhancement effect in the abdominal
aorta (green arrows) can be observed perpendicular to the fold-over direction. White arrows
indicate the renal vein which is located close to the renal artery.
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Figure 5.
Representative examples of the rabbit iliac vessels imaged during incremental dosages of
P904 using T1-weighted and IRON MRA.
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Figure 6.
SNR (A.), CNR (B.) and vessel sharpness (C.) during incremental dosages of P904 and
using IRON versus T1-weighted MRA for imaging.
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